(AOF) – Eli Lilly and Company has completed the acquisition of DICE Therapeutics, Inc. This acquisition expands Lilly’s immunology portfolio to include DICE’s novel oral therapeutic candidates, including oral IL-17 currently in clinical development, to treat chronic diseases in the field of immunology.
Lilly’s tender offer to acquire all of the issued and outstanding shares of DICE common stock, at a purchase price of $48 per share in cash, without interest and net of any applicable withholding taxes, expired on August 8.
When the offer expired, 42,265,390 shares had been validly tendered, representing approximately 88.4% of the issued and outstanding shares.
Eli Lilly says DICE common stock will be delisted from the NASDAQ Global Market.